The New Frontier of GLP-1: Lean People Are Using It for Longevity, Cellular Optimization—Not Weight Loss

Medical injection pen for diabetes management held near person's abdomen
Aesthetic clinics are pairing GLP-1 with nutrition, hormone tracking and resistance training to maintain structure and prevent muscle mass decline.
Courtesy of Vyacheslav at Adobe Stock

GLP-1 has long been associated with weight loss—at least since it was discovered that it had implications beyond diabetes management and migrated into aesthetic practices. However, the drug is now being used by lean individuals, or patients who've never been overweight in their life. Unlike how obese individuals may use this drug as a prelude to cosmetic procedures, many individuals are finding that GLP-1 has longevity benefits for cardiovascular, kidney and liver optimization. For this preventive cellular health biohack, aesthetic physicians are conducting ongoing monitoring, since muscle loss is not the intended outcome but rather a symptom among all users that recent studies indicate needs further clinical investigation.

Evidence affirms the benefits of GLP-1, exceeding the needs of diabetic individuals, with particular reductions in cardiovascular events and mortality. In a 2023 trial conducted by Cleveland Clinic, patients treated with semaglutide lost about 9.4% of their body weight, but also experienced improvements in factors related to cardiovascular disease. Michael Lincoff, MD, who led the study, found that semaglutide reduced the risk of non-fatal stroke by 20%, likely due to GLP-1’s effects on weight loss and decreased ectopic fat deposition [1].

This article is only available to registered users.

Log In to View the Full Article

More in Home